Henry Schein Inc (HSIC) is a publicly traded Healthcare sector company. As of November 3, 2026, HSIC trades at $80.69 with a market cap of $9.46B and a P/E ratio of 27.28. HSIC moved -6.85% today. Year to date, HSIC is +12.64%; over the trailing twelve months it is +36.92%. Its 52-week range spans $60.56 to $92.18. Analyst consensus is buy with an average price target of $98.13. Rallies surfaces HSIC's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Henry Schein raises 2026 EPS outlook; Q3 adjusted EPS rises 13% to $1.56: Henry Schein reported Q3 sales of $3.47 billion, up 4% and slightly below analyst consensus, while adjusted EPS rose 13% to $1.56 and beat estimates. It raised its 2026 adjusted EPS outlook to $5.50-$5.56 and expects adjusted EBITDA growth in the high single digits.
| Metric | Value |
|---|---|
| Price | $80.69 |
| Market Cap | $9.46B |
| P/E Ratio | 27.28 |
| EPS | $3.07 |
| Dividend Yield | 0.00% |
| 52-Week High | $92.18 |
| 52-Week Low | $60.56 |
| Volume | 2.04K |
| Avg Volume | 0 |
| Revenue (TTM) | $12.67B |
| Net Income | $398.00M |
| Gross Margin | 31.69% |
16 analysts cover HSIC: 0 strong buy, 9 buy, 6 hold, 1 sell, 0 strong sell. Consensus rating is buy. Average price target: $98.13.